EP2790722A1 - Composition and method for treating nucleic acid-related eye disease - Google Patents
Composition and method for treating nucleic acid-related eye diseaseInfo
- Publication number
- EP2790722A1 EP2790722A1 EP12858050.3A EP12858050A EP2790722A1 EP 2790722 A1 EP2790722 A1 EP 2790722A1 EP 12858050 A EP12858050 A EP 12858050A EP 2790722 A1 EP2790722 A1 EP 2790722A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- rnase
- composition
- ribonuclease
- nucleic acid
- nuclease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 100
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 63
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 63
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 42
- 208000030533 eye disease Diseases 0.000 title claims abstract description 38
- 101710163270 Nuclease Proteins 0.000 claims description 120
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 111
- 108020004414 DNA Proteins 0.000 claims description 62
- 102000006382 Ribonucleases Human genes 0.000 claims description 34
- 108010083644 Ribonucleases Proteins 0.000 claims description 34
- 206010013774 Dry eye Diseases 0.000 claims description 30
- 239000003112 inhibitor Substances 0.000 claims description 30
- 108060001132 cathelicidin Proteins 0.000 claims description 29
- 102000014509 cathelicidin Human genes 0.000 claims description 29
- 150000001875 compounds Chemical class 0.000 claims description 29
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 28
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 27
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 27
- 239000000523 sample Substances 0.000 claims description 25
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims description 24
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims description 24
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 23
- 102000014150 Interferons Human genes 0.000 claims description 20
- 108010050904 Interferons Proteins 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 239000005557 antagonist Substances 0.000 claims description 19
- 229940079322 interferon Drugs 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims description 17
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims description 17
- 230000003115 biocidal effect Effects 0.000 claims description 17
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 claims description 16
- 108010000303 Secretory Proteinase Inhibitory Proteins Proteins 0.000 claims description 16
- 102000002255 Secretory Proteinase Inhibitory Proteins Human genes 0.000 claims description 16
- 239000003591 leukocyte elastase inhibitor Substances 0.000 claims description 16
- 230000004489 tear production Effects 0.000 claims description 16
- 239000008217 ophthalmic excipient Substances 0.000 claims description 14
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 claims description 13
- 102000005891 Pancreatic ribonuclease Human genes 0.000 claims description 13
- 108010057163 Ribonuclease III Proteins 0.000 claims description 12
- 102000003661 Ribonuclease III Human genes 0.000 claims description 12
- 102000002689 Toll-like receptor Human genes 0.000 claims description 12
- 108020000411 Toll-like receptor Proteins 0.000 claims description 12
- 229940044551 receptor antagonist Drugs 0.000 claims description 11
- 239000002464 receptor antagonist Substances 0.000 claims description 11
- 208000009299 Benign Mucous Membrane Pemphigoid Diseases 0.000 claims description 9
- 208000015200 ocular cicatricial pemphigoid Diseases 0.000 claims description 9
- 229920000642 polymer Polymers 0.000 claims description 9
- 206010065062 Meibomian gland dysfunction Diseases 0.000 claims description 8
- 239000003242 anti bacterial agent Substances 0.000 claims description 8
- 230000003247 decreasing effect Effects 0.000 claims description 8
- 230000007812 deficiency Effects 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 8
- 108010000834 2-5A-dependent ribonuclease Proteins 0.000 claims description 6
- 102100027962 2-5A-dependent ribonuclease Human genes 0.000 claims description 6
- 102100034343 Integrase Human genes 0.000 claims description 6
- 101710203526 Integrase Proteins 0.000 claims description 6
- 108090000621 Ribonuclease P Proteins 0.000 claims description 6
- 102000004167 Ribonuclease P Human genes 0.000 claims description 6
- 108090000638 Ribonuclease R Proteins 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 108010032819 exoribonuclease II Proteins 0.000 claims description 6
- 108010079502 exoribonuclease T Proteins 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 108090000446 ribonuclease T(2) Proteins 0.000 claims description 6
- 108020005403 ribonuclease U2 Proteins 0.000 claims description 6
- 108010050301 tRNA nucleotidyltransferase Proteins 0.000 claims description 6
- 208000035143 Bacterial infection Diseases 0.000 claims description 5
- 102000004533 Endonucleases Human genes 0.000 claims description 5
- 108010042407 Endonucleases Proteins 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 5
- 108010067396 dornase alfa Proteins 0.000 claims description 5
- 206010023332 keratitis Diseases 0.000 claims description 5
- 101001107784 Caenorhabditis elegans Deoxyribonuclease-2 Proteins 0.000 claims description 4
- 108010002700 Exoribonucleases Proteins 0.000 claims description 4
- 102000004678 Exoribonucleases Human genes 0.000 claims description 4
- 206010060833 Infectious crystalline keratopathy Diseases 0.000 claims description 4
- 206010014801 endophthalmitis Diseases 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 208000005494 xerophthalmia Diseases 0.000 claims description 4
- 206010071683 Diffuse lamellar keratitis Diseases 0.000 claims description 3
- 108060002716 Exonuclease Proteins 0.000 claims description 3
- 108010059724 Micrococcal Nuclease Proteins 0.000 claims description 3
- 102100029683 Ribonuclease T2 Human genes 0.000 claims description 3
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 claims description 3
- 230000003266 anti-allergic effect Effects 0.000 claims description 3
- 239000013068 control sample Substances 0.000 claims description 3
- 108010002712 deoxyribonuclease II Proteins 0.000 claims description 3
- 102000013165 exonuclease Human genes 0.000 claims description 3
- 102000005549 oligoribonuclease Human genes 0.000 claims description 3
- 108020002020 oligoribonuclease Proteins 0.000 claims description 3
- 108010066538 ribonuclease V Proteins 0.000 claims description 3
- 150000003431 steroids Chemical class 0.000 claims description 3
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 230000032770 biofilm formation Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000003595 mist Substances 0.000 claims description 2
- 229940107568 pulmozyme Drugs 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 34
- 230000000694 effects Effects 0.000 description 30
- 210000000440 neutrophil Anatomy 0.000 description 30
- 108010028275 Leukocyte Elastase Proteins 0.000 description 27
- 102000016799 Leukocyte elastase Human genes 0.000 description 27
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 26
- 239000012530 fluid Substances 0.000 description 20
- -1 neutrophils Proteins 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- 108010033040 Histones Proteins 0.000 description 17
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 15
- 238000003556 assay Methods 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 239000000975 dye Substances 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 239000000123 paper Substances 0.000 description 12
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 11
- 230000000840 anti-viral effect Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 102000006947 Histones Human genes 0.000 description 9
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 9
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 210000000795 conjunctiva Anatomy 0.000 description 9
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 5
- 238000003125 immunofluorescent labeling Methods 0.000 description 5
- 210000004561 lacrimal apparatus Anatomy 0.000 description 5
- 238000000370 laser capture micro-dissection Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 229910000077 silane Inorganic materials 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 101150053046 MYD88 gene Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 229960002227 clindamycin Drugs 0.000 description 4
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 4
- 235000019271 petrolatum Nutrition 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 210000003296 saliva Anatomy 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 238000000116 DAPI staining Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 102000003996 Interferon-beta Human genes 0.000 description 3
- 108090000467 Interferon-beta Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- 229940120195 Toll-like receptor 9 antagonist Drugs 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 108010059993 Vancomycin Proteins 0.000 description 3
- 230000000172 allergic effect Effects 0.000 description 3
- 229960000723 ampicillin Drugs 0.000 description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004624 confocal microscopy Methods 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 239000011824 nuclear material Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- 229960003165 vancomycin Drugs 0.000 description 3
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 3
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- XMGQYMWWDOXHJM-JTQLQIEISA-N (+)-α-limonene Chemical compound CC(=C)[C@@H]1CCC(C)=CC1 XMGQYMWWDOXHJM-JTQLQIEISA-N 0.000 description 2
- MMWFQFGXFPTUIF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C MMWFQFGXFPTUIF-UHFFFAOYSA-N 0.000 description 2
- SMCMGLCPSSSOQE-NTZARQNWSA-N 4-n-(4-chlorophenyl)sulfonyl-1-n-[(2s)-3-methyl-1-oxo-1-[[(2s)-1-(1,1,1-trifluoro-4-methyl-2-oxopentan-3-yl)pyrrolidine-2-carbonyl]amino]butan-2-yl]benzene-1,4-dicarboxamide Chemical compound N([C@@H](C(C)C)C(=O)NC(=O)[C@H]1N(CCC1)C(C(C)C)C(=O)C(F)(F)F)C(=O)C(C=C1)=CC=C1C(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 SMCMGLCPSSSOQE-NTZARQNWSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 229940123672 Cadherin antagonist Drugs 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XQSPYNMVSIKCOC-NTSWFWBYSA-N Emtricitabine Chemical compound C1=C(F)C(N)=NC(=O)N1[C@H]1O[C@@H](CO)SC1 XQSPYNMVSIKCOC-NTSWFWBYSA-N 0.000 description 2
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 2
- 229920002444 Exopolysaccharide Polymers 0.000 description 2
- 208000001860 Eye Infections Diseases 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 108010084635 ICI 200880 Proteins 0.000 description 2
- 229940123038 Integrin antagonist Drugs 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 229940123578 Selectin antagonist Drugs 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 241000191940 Staphylococcus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 108010019752 ZD 8321 Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940038195 amoxicillin / clavulanate Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940121357 antivirals Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000004397 blinking Effects 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229960001388 interferon-beta Drugs 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- ZWRUINPWMLAQRD-UHFFFAOYSA-N nonan-1-ol Chemical compound CCCCCCCCCO ZWRUINPWMLAQRD-UHFFFAOYSA-N 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical class 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002412 selectin antagonist Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- BTGNGJJLZOIYID-UHFFFAOYSA-N sivelestat Chemical compound C1=CC(OC(=O)C(C)(C)C)=CC=C1S(=O)(=O)NC1=CC=CC=C1C(=O)NCC(O)=O BTGNGJJLZOIYID-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229960001922 sodium perborate Drugs 0.000 description 2
- YKLJGMBLPUQQOI-UHFFFAOYSA-M sodium;oxidooxy(oxo)borane Chemical compound [Na+].[O-]OB=O YKLJGMBLPUQQOI-UHFFFAOYSA-M 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 239000003871 white petrolatum Substances 0.000 description 2
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- BTNGSKFFUFQWEO-UHFFFAOYSA-N (4-ethenylphenyl)methyl 2-methylprop-2-enoate (4-ethenylphenyl)-tris(trimethylsilyloxy)silane 1-ethenylpyrrolidin-2-one 1,1,1,3,3,3-hexafluoropropan-2-yl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCOC(=O)C(C)=C.CC(=C)C(=O)OCc1ccc(C=C)cc1.CC(=C)C(=O)OC(C(F)(F)F)C(F)(F)F.C[Si](C)(C)O[Si](O[Si](C)(C)C)(O[Si](C)(C)C)c1ccc(C=C)cc1 BTNGSKFFUFQWEO-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- PQMFVUNERGGBPG-UHFFFAOYSA-N (6-bromopyridin-2-yl)hydrazine Chemical compound NNC1=CC=CC(Br)=N1 PQMFVUNERGGBPG-UHFFFAOYSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- NXBDLTJZZIKTKL-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C NXBDLTJZZIKTKL-UHFFFAOYSA-N 0.000 description 1
- GNTAAQBKCCJXGF-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one methyl 2-methylprop-2-enoate 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C.CC(=C)C(=O)OCCOC(=O)C(C)=C GNTAAQBKCCJXGF-UHFFFAOYSA-N 0.000 description 1
- SVKHOOHZPMBIGM-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.C=CN1CCCC1=O.CC(=C)C(=O)OCCO SVKHOOHZPMBIGM-UHFFFAOYSA-N 0.000 description 1
- HVYQZCLEPABLCN-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;methyl 2-methylprop-2-enoate;prop-2-enyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.C=CN1CCCC1=O.CC(=C)C(=O)OCC=C HVYQZCLEPABLCN-UHFFFAOYSA-N 0.000 description 1
- NZJXADCEESMBPW-UHFFFAOYSA-N 1-methylsulfinyldecane Chemical compound CCCCCCCCCCS(C)=O NZJXADCEESMBPW-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- XPSXBEJFSQZTBS-UHFFFAOYSA-N 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate N-(2-methyl-4-oxopentan-2-yl)prop-2-enamide Chemical compound CC(=C)C(=O)OCCO.CC(=O)CC(C)(C)NC(=O)C=C.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C XPSXBEJFSQZTBS-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- YSIHYROEMJSOAS-UHFFFAOYSA-N 2-(5-amino-6-oxo-2-phenylpyrimidin-1-yl)-n-[1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide Chemical compound N=1N=C(C(C)(C)C)OC=1C(=O)C(C(C)C)NC(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 YSIHYROEMJSOAS-UHFFFAOYSA-N 0.000 description 1
- KKOWZRLUUCIGQY-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C KKOWZRLUUCIGQY-UHFFFAOYSA-N 0.000 description 1
- PVISMVGVPWOQMG-UHFFFAOYSA-N 2-hydroxyethyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C PVISMVGVPWOQMG-UHFFFAOYSA-N 0.000 description 1
- UURVHRGPGCBHIC-UHFFFAOYSA-N 3-(ethenoxycarbonylamino)propanoic acid 4-[[[[[[[[[[[[[[[[[[[[[[[[[[[4-ethenoxycarbonyloxybutyl(dimethyl)silyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]oxy-dimethylsilyl]butyl ethenyl carbonate 1-ethenylpyrrolidin-2-one ethenyl N-[3-tris(trimethylsilyloxy)silylpropyl]carbamate Chemical compound C=CN1CCCC1=O.OC(=O)CCNC(=O)OC=C.C[Si](C)(C)O[Si](CCCNC(=O)OC=C)(O[Si](C)(C)C)O[Si](C)(C)C.C[Si](C)(CCCCOC(=O)OC=C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)CCCCOC(=O)OC=C UURVHRGPGCBHIC-UHFFFAOYSA-N 0.000 description 1
- ZOPSJJCUEOEROC-NSQCPRBHSA-N 3-[[butyl(dimethyl)silyl]oxy-dimethylsilyl]propyl 2-methylprop-2-enoate;n,n-dimethylprop-2-enamide;1-ethenylpyrrolidin-2-one;2-hydroxyethyl 2-methylprop-2-enoate;[(2r)-2-hydroxy-3-[3-[methyl-bis(trimethylsilyloxy)silyl]propoxy]propyl] 2-methylprop-2-enoat Chemical compound CN(C)C(=O)C=C.C=CN1CCCC1=O.CC(=C)C(=O)OCCO.CC(=C)C(=O)OCCOC(=O)C(C)=C.CCCC[Si](C)(C)O[Si](C)(C)CCCOC(=O)C(C)=C.CC(=C)C(=O)OC[C@H](O)COCCC[Si](C)(O[Si](C)(C)C)O[Si](C)(C)C ZOPSJJCUEOEROC-NSQCPRBHSA-N 0.000 description 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- 239000005725 8-Hydroxyquinoline Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 1
- 102000011750 Endodeoxyribonucleases Human genes 0.000 description 1
- 108010037179 Endodeoxyribonucleases Proteins 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 108010032976 Enfuvirtide Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 108010009832 Exodeoxyribonucleases Proteins 0.000 description 1
- 102000009788 Exodeoxyribonucleases Human genes 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 102100039869 Histone H2B type F-S Human genes 0.000 description 1
- 101100281953 Homo sapiens GAPDH gene Proteins 0.000 description 1
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021580 Inadequate lubrication Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- JSHDAORXSNJOBA-UHFFFAOYSA-N Isopropyl hexanoate Chemical compound CCCCCC(=O)OC(C)C JSHDAORXSNJOBA-UHFFFAOYSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- KJHKTHWMRKYKJE-SUGCFTRWSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O KJHKTHWMRKYKJE-SUGCFTRWSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- TYMRLRRVMHJFTF-UHFFFAOYSA-N Mafenide Chemical compound NCC1=CC=C(S(N)(=O)=O)C=C1 TYMRLRRVMHJFTF-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 102100038610 Myeloperoxidase Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical class CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- KJHOZAZQWVKILO-UHFFFAOYSA-N N-(diaminomethylidene)-4-morpholinecarboximidamide Chemical compound NC(N)=NC(=N)N1CCOCC1 KJHOZAZQWVKILO-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical class C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001616 Polymacon Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- WPVFJKSGQUFQAP-UHFFFAOYSA-N [2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]-3-hydroxypropyl] 2-amino-3-methylbutanoate Chemical compound N1C(N)=NC(=O)C2=C1N(COC(CO)COC(=O)C(N)C(C)C)C=N2 WPVFJKSGQUFQAP-UHFFFAOYSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- MCGSCOLBFJQGHM-SCZZXKLOSA-N abacavir Chemical compound C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 MCGSCOLBFJQGHM-SCZZXKLOSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 229960001997 adefovir Drugs 0.000 description 1
- WOZSCQDILHKSGG-UHFFFAOYSA-N adefovir depivoxil Chemical compound N1=CN=C2N(CCOCP(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C)C=NC2=C1N WOZSCQDILHKSGG-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229960001830 amprenavir Drugs 0.000 description 1
- YMARZQAQMVYCKC-OEMFJLHTSA-N amprenavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 YMARZQAQMVYCKC-OEMFJLHTSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- IMNFDUFMRHMDMM-UHFFFAOYSA-N anhydrous n-heptane Natural products CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 1
- 230000002583 anti-histone Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 229940068561 atripla Drugs 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960003623 azlocillin Drugs 0.000 description 1
- JTWOMNBEOCYFNV-NFFDBFGFSA-N azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 210000000321 buccal mucosa cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000010405 clearance mechanism Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 229940047766 co-trimoxazole Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000002247 constant time method Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960005107 darunavir Drugs 0.000 description 1
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960001585 dicloxacillin Drugs 0.000 description 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 description 1
- 229960002656 didanosine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 description 1
- 229960004100 dirithromycin Drugs 0.000 description 1
- LNGNZSMIUVQZOX-UHFFFAOYSA-L disodium;dioxido(sulfanylidene)-$l^{4}-sulfane Chemical compound [Na+].[Na+].[O-]S([O-])=S LNGNZSMIUVQZOX-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 229960002030 edoxudine Drugs 0.000 description 1
- XACKNLSZYYIACO-DJLDLDEBSA-N edoxudine Chemical compound O=C1NC(=O)C(CC)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XACKNLSZYYIACO-DJLDLDEBSA-N 0.000 description 1
- 229960003804 efavirenz Drugs 0.000 description 1
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 1
- 229960000366 emtricitabine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- PEASPLKKXBYDKL-FXEVSJAOSA-N enfuvirtide Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C1=CN=CN1 PEASPLKKXBYDKL-FXEVSJAOSA-N 0.000 description 1
- 229960002062 enfuvirtide Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229960002549 enoxacin Drugs 0.000 description 1
- IDYZIJYBMGIQMJ-UHFFFAOYSA-N enoxacin Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 IDYZIJYBMGIQMJ-UHFFFAOYSA-N 0.000 description 1
- 229960000980 entecavir Drugs 0.000 description 1
- YXPVEXCTPGULBZ-WQYNNSOESA-N entecavir hydrate Chemical compound O.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)C1=C YXPVEXCTPGULBZ-WQYNNSOESA-N 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- XCWFZHPEARLXJI-UHFFFAOYSA-N fomivirsen Chemical compound C1C(N2C3=C(C(NC(N)=N3)=O)N=C2)OC(CO)C1OP(O)(=S)OCC1OC(N(C)C(=O)\N=C(\N)C=C)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C(NC(=O)C(C)=C2)=O)CC1OP(O)(=S)OCC1OC(N2C3=C(C(NC(N)=N3)=O)N=C2)CC1OP(O)(=S)OCC1OC(N2C(N=C(N)C=C2)=O)CC1OP(O)(=S)OCC(C(C1)OP(S)(=O)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OCC2C(CC(O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OCC2C(CC(O2)N2C3=C(C(NC(N)=N3)=O)N=C2)O)OC1N1C=C(C)C(=O)NC1=O XCWFZHPEARLXJI-UHFFFAOYSA-N 0.000 description 1
- 229960001447 fomivirsen Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003142 fosamprenavir Drugs 0.000 description 1
- MLBVMOWEQCZNCC-OEMFJLHTSA-N fosamprenavir Chemical compound C([C@@H]([C@H](OP(O)(O)=O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1COCC1)C1=CC=CC=C1 MLBVMOWEQCZNCC-OEMFJLHTSA-N 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- TZMQHOJDDMFGQX-UHFFFAOYSA-N hexane-1,1,1-triol Chemical compound CCCCCC(O)(O)O TZMQHOJDDMFGQX-UHFFFAOYSA-N 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- WEVJJMPVVFNAHZ-RRKCRQDMSA-N ibacitabine Chemical compound C1=C(I)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 WEVJJMPVVFNAHZ-RRKCRQDMSA-N 0.000 description 1
- 229960000374 ibacitabine Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229960001936 indinavir Drugs 0.000 description 1
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 244000000056 intracellular parasite Species 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 210000005201 lateral eyelid Anatomy 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002422 lomefloxacin Drugs 0.000 description 1
- ZEKZLJVOYLTDKK-UHFFFAOYSA-N lomefloxacin Chemical compound FC1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNC(C)C1 ZEKZLJVOYLTDKK-UHFFFAOYSA-N 0.000 description 1
- 229960004525 lopinavir Drugs 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 229960003640 mafenide Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229960004710 maraviroc Drugs 0.000 description 1
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- VTPNPMGMYAMEJY-UHFFFAOYSA-N methyl 2-methylprop-2-enoate 2-methylprop-2-enoic acid 2-[2-[2-[2-(2-methylprop-2-enoyloxy)ethoxy]ethoxy]ethoxy]ethyl 2-methylprop-2-enoate 3-tris[[dimethyl(trimethylsilyloxy)silyl]oxy]silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(O)=O.COC(=O)C(C)=C.CC(=C)C(=O)OCCOCCOCCOCCOC(=O)C(C)=C.CC(=C)C(=O)OCCC[Si](O[Si](C)(C)O[Si](C)(C)C)(O[Si](C)(C)O[Si](C)(C)C)O[Si](C)(C)O[Si](C)(C)C VTPNPMGMYAMEJY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960000198 mezlocillin Drugs 0.000 description 1
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 description 1
- 238000001531 micro-dissection Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960005389 moroxydine Drugs 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229960000515 nafcillin Drugs 0.000 description 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- HMPQTEPEMQZWQH-QZTJIDSGSA-N ono-6818 Chemical compound N([C@H](C(C)C)[C@@H](O)C=1OC(=NN=1)C(C)(C)C)C(=O)CN(C(C(N)=CN=1)=O)C=1C1=CC=CC=C1 HMPQTEPEMQZWQH-QZTJIDSGSA-N 0.000 description 1
- 229940096984 ophthalmic cream Drugs 0.000 description 1
- 229940100655 ophthalmic gel Drugs 0.000 description 1
- 229940069265 ophthalmic ointment Drugs 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 229960003540 oxyquinoline Drugs 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- KQOXLKOJHVFTRN-UHFFFAOYSA-N pleconaril Chemical compound O1N=C(C)C=C1CCCOC1=C(C)C=C(C=2N=C(ON=2)C(F)(F)F)C=C1C KQOXLKOJHVFTRN-UHFFFAOYSA-N 0.000 description 1
- 229960000471 pleconaril Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068917 polyethylene glycols Drugs 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical class O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229940053174 restasis Drugs 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 229960001852 saquinavir Drugs 0.000 description 1
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NLAIHECABDOZBR-UHFFFAOYSA-M sodium 2,2-bis(2-methylprop-2-enoyloxymethyl)butyl 2-methylprop-2-enoate 2-hydroxyethyl 2-methylprop-2-enoate 2-methylprop-2-enoate Chemical compound [Na+].CC(=C)C([O-])=O.CC(=C)C(=O)OCCO.CCC(COC(=O)C(C)=C)(COC(=O)C(C)=C)COC(=O)C(C)=C NLAIHECABDOZBR-UHFFFAOYSA-M 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960005158 sulfamethizole Drugs 0.000 description 1
- VACCAVUAMIDAGB-UHFFFAOYSA-N sulfamethizole Chemical compound S1C(C)=NN=C1NS(=O)(=O)C1=CC=C(N)C=C1 VACCAVUAMIDAGB-UHFFFAOYSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000004488 tear evaporation Effects 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 229960002935 telaprevir Drugs 0.000 description 1
- 108010017101 telaprevir Proteins 0.000 description 1
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 1
- 229960004556 tenofovir Drugs 0.000 description 1
- SGOIRFVFHAKUTI-ZCFIWIBFSA-N tenofovir (anhydrous) Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(O)=O)C=NC2=C1N SGOIRFVFHAKUTI-ZCFIWIBFSA-N 0.000 description 1
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960004659 ticarcillin Drugs 0.000 description 1
- OHKOGUYZJXTSFX-KZFFXBSXSA-N ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960005041 troleandomycin Drugs 0.000 description 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 description 1
- 229960000497 trovafloxacin Drugs 0.000 description 1
- WVPSKSLAZQPAKQ-CDMJZVDBSA-N trovafloxacin Chemical compound C([C@H]1[C@@H]([C@H]1C1)N)N1C(C(=CC=1C(=O)C(C(O)=O)=C2)F)=NC=1N2C1=CC=C(F)C=C1F WVPSKSLAZQPAKQ-CDMJZVDBSA-N 0.000 description 1
- 229940008349 truvada Drugs 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- ARAIBEBZBOPLMB-UFGQHTETSA-N zanamivir Chemical compound CC(=O)N[C@@H]1[C@@H](N=C(N)N)C=C(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO ARAIBEBZBOPLMB-UFGQHTETSA-N 0.000 description 1
- 229960001028 zanamivir Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- This application includes a sequence listing in accordance with 37 C.F.R. ⁇ 1.821-1.825.
- the sequence listing is contained in a file named "11738468_l.txt” (790 bytes, created on August 14, 2012) and it is hereby incorporated by reference.
- the present invention relates to a composition and method for treating nucleic acid- related eye disease.
- the ocular surface epithelium undergoes continuous, dynamic turnover, which is part of a normal shedding process. This turnover is increased in subjects suffering from various forms of nucleic acid-related eye disease, such as dry eye disease (DED).
- DED dry eye disease
- Superficial corneal cells are shed into the precorneal tear film.
- the corneal epithelial cell shedding process, or desquamation, is regulated by apoptotic mechanisms.
- Dead and dying cells release nucleic acid, a type of damage-associated molecular pattern molecule, which can stimulate the innate immune system and link it to adaptive immune system.
- Extracellular DNA strands for example, have been reported in corneal filaments, which are frequently present on the corneas of patients with DED.
- Tear fluid contains several neutrophil extracellular trap (NET) components.
- Neutrophils undergo a low level of recruitment on the ocular surface, and numerous neutrophils are present in the tear film during ocular surface inflammation, which has a prominent role in symptom development and amplification.
- Neutrophil elastase and histone proteins have also been reported in tear fluid. These reports document the presence of extracellular DNA, histones, neutrophils, neutrophil elastase, and nucleases in tear fluid and perhaps suggest mechanisms exist for the continual production and clearance of extracellular DNA in tear film.
- Extracellular DNA in tear film may play a role in the pathology associated with nucleic acid-related eye disease.
- Nucleic acid-related eye diseases that may be associated with the formation of ocular mucoid films and/or biofilms present potentially disabling conditions, which adversely impact the vision-related quality of life. They can lead to ocular discomfort and/or deterioration in visual performance, such as reading speed and contrast sensitivity.
- nucleic acid-related eye diseases Despite the high incidence of nucleic acid-related eye diseases, there is currently no consistently effective treatment for these conditions. Because hyperosmolarity and inflammation have traditionally been thought as central reasons for dry eye disease, for example, current treatments focus on the use of eye-lid hygiene, topical antibiotics, oral tetracyclines, antiinflammatories and/or corticosteroids. Such treatments are often ineffective or variably effective. As such there is a need for new therapeutic modalities to treat nucleic acid-related eye diseases, such as DED, that can result from the production/formation of nucleic acid in conjunction with ocular mucoid films and/or biofilms, for example.
- DED nucleic acid-related eye diseases
- nucleic acid-related eye diseases are associated with poor tear quality, which may be related to nucleic acid biofilm/mucoid film formation on the surface of the eye or inside the eye.
- the nucleic acid may be extracellular.
- One such disease is dry eye disease (DED).
- the composition may comprise nuclease and an ophthalmic excipient.
- the nuclease may be a DNase or an RNase, or a combination thereof.
- the nuclease may be an endonuclease or an exonuclease.
- the DNase may be Deoxyribonuclease I (DNase I); Deoxyribonuclease II (DNase II); Deoxyribonuclease III, or a micrococcal nuclease.
- the RNase may be Ribonuclease A (RNase A); Ribonuclease H (RNase H); Ribonuclease I (RNase I); Ribonuclease II (RNase II); Ribonuclease III (RNase III);
- Ribonuclease D Ribonuclease D
- Ribonuclease L Ribonuclease L
- Ribonuclease P Ribonuclease P
- Ribonuclease PH Ribonuclease PH
- Ribonuclease PhyM Ribonuclease R
- Ribonuclease T Ribonuclease Tl
- Ribonuclease T2 Ribonuclease T2;
- Ribonuclease U2 Ribonuclease U2
- Ribonuclease VI Ribonuclease VI
- Ribonuclease V Ribonuclease V
- the DNase or RNase may be recombinant.
- the composition may further comprise an antagonist or inhibitor.
- the antagonist or inhibitor may be selected from the group consisting of an antibiotic compound, toll-like receptor antagonist, type-1 interferon antagonist, cathelicidin inhibitor, a MyD88 inhibitor, a steroid, an anti-allergy compound, and a neutrophil elastase inhibitor, and combinations thereof.
- the method may comprise administering the above-described nuclease composition with an ophthalmic excipient to the eye in an amount effective to treat the eye disease.
- the ocular surface of the eye may contain a tear film, which may be a biofilm or a mucoid film.
- the biofilm or mucoid film may contain nucleic acid.
- the nucleic acid may be extracellular nucleic acid.
- the nucleic acid may be DNA, RNA, or a combination thereof.
- the tear film may contain less than 3.14 ng/ml of nuclease prior to administering the composition.
- the tear film may contain less than 0.05 Kunitz units of nuclease activity prior to administering the composition.
- An effective amount of the composition may contain between 5 ng/ml and 3 mg/ml of the nuclease.
- An effective amount of the composition may contain between 100 ng/ml and 200 ng/ml of the nuclease.
- the nucleic acid-related eye disease may be DED, diffuse lamellar keratitis, contact lens- associated keratitis, endophthalmitis, or infectious crystalline keratopathy, ocular cicatricial pemphigoid (OCP), keratoconjunctivitis sicca (KCS), Sjogren syndrome (SS), Sjogren syndrome associated keratoconjunctivitis sicca, non-Sjogren syndrome associated keratoconjunctivitis sicca, keratitis sicca, sicca syndrome, xerophthalmia, tear film disorder, decreased tear production, aqueous tear deficiency (ATD), or meibomian gland dysfunction (MGD).
- OCP ocular cicatricial pemphigoid
- KCS keratoconjunctivitis sicca
- SS Sjogren syndrome associated keratoconjunctivitis sicca
- the DED may be an autoimmune DED or a DED associated with Sjorgren's syndrome, for example.
- the DED may be attributable to one or more causes including: aging, contact lens usage and medication usage.
- the antibiotic may be ampicillin, amoxicillin/clavulanate, metronidazole, clindamycin, erythromycin, gentamicin, vancomycin, ciproflaxin, clindamycin, tetracycline, an anxiolytic, or a combination thereof.
- the toll-like receptor antagonist may be an oligonucleotide comprising the sequence TTAGGG.
- the oligonucleotide may consist of the sequence
- the type-1 interferon antagonist may be any compound that antagonizes or competitively inhibits type I interferon binding to its receptor, such as receptor subunits IFNAR-1 and/or IFNR-2.
- the compound may be an anti- IFNa antibody.
- the cathelicidin inhibitor may be a bacterial exopolysaccharide.
- the neutrophil elastase inhitor may be selected from the group consisting of ONO-5046, MR-889, L-694,458, CE-1037, GW-311616 TEI-8362, ONO-6818, AE-3763, FK-706, ICI-200,880, ZD-0892 and ZD-8321.
- the method may comprise collecting a tear sample from a subject. This sample may be contacted with a dye that binds to DNA, such as picogreen. Alternatively, the sample may be contacted with a DNase and then contacted with the dye. The intensity of the color may be measured and compared to the intensity of dye fluorescence in a normal control sample. An increased level of dye fluorescence intensity in the sample as compared to the control may be indicative of a dry eye disease.
- Also provided herein is a method for treating an ocular bacterial infection.
- the method comprises administering a composition comprising a nuclease to the eye in an amount effective to treat the infection.
- the composition may be injected into the eye.
- FIG. 1 shows a schematic of the biology of DED.
- Extracellular DNA is found on the ocular surface of eyes affected by DED. This extracellular DNA may come from two major sources: neutrophils and conjunctival and other corneal cells. Neutrophil extracellular DNA forms neutrophil extracellular traps (NETs). These NETs have inflammatory and angiogneic molecules, such as cathelicidin, neutrophil elastase, and histone associated with them.
- TLR9 toll-like receptor 9
- Figure 2 shows cells transferred on silane coated adhesive slides and stained by hematoxylin and eosin. The nuclei and strands are stained by hematoxyline showing the presence of intracellular and extracellular DNA respectively, further indicating the presence of NETs.
- Figure 3 shows a confocal image (63X) of indirect immunofluorescence stained with DAPI stain for nucleic acid. The stain is picked up by the cell nucleus as well as by extracellular DNA strands. Figure 3 shows the presence of extracellular DNA, which is important for the formation of NETs.
- Figure 4 shows the presence of neutrophils and strands coming out from cells as extracellular DNA.
- the cells were first stained with indirect immunofluorescence.
- B shows extracellular strand like structure revealing nuclear and extracellular DNA.
- the cells were then washed and stained with hematoxylin and eosin to confirm the presence of neutrophil and the strand coming out from the cell thereby confirming the presence of NETs.
- Figure 5 shows a confocal image, whereby cells are indirectly immunofluoresced with primary antibody against neutrophil elastase, histone and DAPI. Granular staining for neutrophil elastase co-localizes with histone and nucleic acid.
- Figure 6 shows the presence of NETs on the ocular surface (A). After treatment with DNase, stranded extracellular DNA disappears, while cellular intregrity is maintained (B). The two samples (A) and (B) were collected from the same subject. Sample A was treated with PBS for 20 minutes then stained with DAPI. Sample B was treated with DNase (100 IU/ml) for 20 minutes and stained with DAPI.
- Figure 7 show confirmation of the presence of NETs and differentiating them from mucous on the ocular surface.
- a specimen of mucous from the conjunctival surface was stained with DAPI. The nucleus was stained; however, the mucous was not stained.
- Figure 8 further confirms the presence of mucous from the same subject from which the specimen was obtained in Figure 7.
- the specimen was stained with Periodic Acid Schiff (PAS).
- PAS Periodic Acid Schiff
- Figure 9 shows a graph for dry eye (with Schirmer's Test ⁇ 5) compared to normal tear production (with Schirmer's Test > 5) with standard deviation in error bars.
- the optical density in dry eye is greater (17834.14) than in normal tear production (12609.86).
- the amount of extracellular DNA obtained from Schirmer's filter paper is greater compared to Schirmer's with normal tear production.
- Figure 10 shows quantitative real-time PCR data regarding the level of Interferon alpha 1, interferon beta, TLR-9, and Myd88 genes in humans with severe dry eye cells as compared to humans with normal tear production (no dry eye).
- the levels of these genes are several fold increased in the conjunctiva of patients with dry eyes and tear deficiency.
- These pathways (TLR-9 and Myd88) are stimulated by extracellular DNA, thus providing receptor and transcriptionial data support for the stimulation of ocular surface inflammation by extracellular DNA.
- the downstream mediators of inflammation are also increased in dry eye patients.
- Figure 11 shows material derived from Schirmer test strip impressions.
- E Confocal immunofluorescence staining image shows that histones (El, green), neutrophil elastase (E2, red), and eDNA (E3, Blue) are the molecular components of NETs (E4, overlay). Arrowhead indicates a NET strand. Inset in E2 shows neutrophils with DAPI- stained multilobed nucleus. Scale bars: B, CI, C2, and D (50 ⁇ ); El and E2 inset (10 ⁇ ).
- Figure 12 shows eDNA and neutrophil extracellular traps (NETs) in mucoid films.
- A Clinical photographs of eyes of patients with severe tear deficient DED. Arrowhead indicates a mucoid film over the cornea and bulbar conjunctiva (Al), and inferior fornix (A2). Inset shows magnified view of mucoid films.
- B cytological examination of the mucoid films.
- Bl H&E staining shows the surface epithelial cells and numerous neutrophils.
- B2 DAPI staining shows the presence of eDNA strands (arrowhead) and multilobed nucleus of neutrophils.
- B3 eDNA and neutrophil extracellular traps
- Neutrophil elastase immuno staining confirms the presence of neutrophils.
- C Confocal immunofluorescent staining image shows that neutrophil elastase (CI, red), histones (C2, green), and eDNA (C3, Blue) are molecular components of NETs (C4, overlay). Arrowhead indicates a NET strand.
- D Laser capture microdissection (LCM) was performed to capture DAPI- stained strands to confirm the presence of DNA in them. In Dl, arrowhead indicates an eDNA strand. In D2, asterisk occupies the area of the strand post LCM. (03): GAPDH PCR product in eDNA strand lane confirms the presence of DNA material. Scale bars: Bl, B2, and B3 (20 ⁇ ); C, Dl. and D2 (50 ⁇ ).
- FIG. 13 shows neutrophils
- A1-A4 Cathelicidin (green) is present in mucoid films (Al, arrow) and eDNA strands (Al, arrowhead). Cathelicidin colocalizes with neutrophil elastase (A2, red) and DAPI nuclear stain (A3, blue).
- B1-B4) Cathelicidin (green) is present in neutrophils (Bl, arrowhead) and colocalizes with neutrophil elastase (B2, red) and DAPI (B3, blue).
- C1-C4) Cathelicidin (CI, arrowhead) and DAPI- stained nuclear material (C3, arrowhead) are extruded from a neutrophil to form NETs. Scale bars: 10 ⁇ .
- Figure 14 shows gene expression in DED patients and controls.
- A The average aqueous tear production, measured using Schirmer I test, was significantly lower in DED patients.
- B eDNA length was measured after impression of Schirmer strip on a glass slide. The eDNA length was significantly greater in DED patients.
- C eDNA amount on the Schirmer strips was measured using Picogreen assay. DED patients have significantly greater eDNA amounts.
- D Genes in the eDNA signal transduction pathway were significantly overexpressed in exfoliated conjunctival cells from DED patients.
- E Inflammatory gene expression was also significantly increased in DED patients.* p ⁇ 0.05.
- Figure 15 shows Nucleases and DNase I are present in tear fluid (A1-A6):
- FIG. 16 shows mucoid films plated onto bacterial culture plates. Patients with severe tear deficient dry eye disease may have mucoid films on the ocular surface. Mucoid films were lifted from the ocular surface using a sterile eSwab. Growth of Gram positive cocci was observed which were identified as coagulase negative staphylococcus species.
- A Blood Agar culture plate shows pin head bacterial colonies.
- nucleic acid-related eye diseases such as DED, and DED-related conditions
- NETs neutrophil extracellular traps
- NETs are extracellular structures composed of chromatin, which includes nucleic acid, such as DNA; neutrophil elastase; histone; and granule proteins. NETs can provide local concentrations of antimicrobial activity and, accordingly, are prevalent at inflammatory sites.
- Control as used herein may mean a composition or sample known to not have a dry eye disease or be bacterially infected (a negative control).
- a positive control may mean a sample that harbors a nucleic acid-related eye disease, or is bacterially infected. Any control may comprise a known amount of extracellular DNA.
- each intervening number there between with the same degree of precision is explicitly contemplated.
- the numbers 7 and 8 are contemplated in addition to 6 and 9, and for the range 6.0-7.0, the number 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, and 7.0 are explicitly contemplated.
- nuclease composition that is capable of removing nucleic acid from the surface of the eye or inside the eye.
- the nucleic acid may be extracellular.
- the nuclease composition may contain one or more nucleases.
- the nuclease may be a DNase or an RNase.
- the nuclease composition may also contain an ophthalmic excipient.
- the nuclease composition may futher contain one or more an antibiotic compound, anti-viral compound, an anti-inflammatory, a toll-like receptor antagonist, a type- 1 interferon antagonist, a cathelicidin inhibitor, MyD88 inhibitor, steroid, anti-allergy compound, and/or a neutrophil elastase inhibitor.
- the nuclease composition may not contain any of an antibiotic compound, an anti- viral compound, an anti-inflammatory, a toll-like receptor antagonist, a type- 1 interferon antagonist, a cathelicidin inhibitor, and/or a neutrophil elastase inhibitor, but rather may be used in combination with one or more of antibiotic compounds, toll- like receptor antagonists, type-1 interferon antagonists, cathelicidin inhibitors, and/or a neutrophil elastase inhibitors.
- the pH and/or the osmolarity of the nuclease composition may be appropriately adjusted prior to use.
- the pH of the nuclease composition may be between 4 and 9, between 5 and 8, between 6 and 7, or between 6.5 and 7.5.
- the pH of the nuclease composition may be 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9.
- the pH of the nuclease may be 7.4.
- the osmolarity of the nuclease composition may be hypo-osmolar or iso-osmolar.
- the DNase composition may have an osmolarity of between 100 mOsm/liter and 500 mOsm/liter, 150 mOsm/liter and 450 mOsm/liter, 200 mOsm/liter and 400 mOsm/liter, 250 mOsm/liter and 350 mOsm/liter, 275 mOsm/liter and 325 mOsm/liter, 100 mOsm/liter and 150 mOsm/liter, 150 mOsm/liter and 200 mOsm/liter, 150 mOsm/liter and 300 mOsm/liter, 200 mOsm/liter and 300 mOsm/liter, 0 mOsm/liter and 100 mOsm/liter, 25 mOsm/liter and 75 mOsm/liter,
- the nucleases contemplated in the present invention include DNases and RNases.
- the DNase may be any enzyme that catalyzes the hydrolytic cleavage of phosphodiester linkages in a DNA backbone.
- One such enzyme is a deoxyribonuclease.
- deoxyribonucleases include, but are not limited to: Deoxyribonuclease I (DNase I);
- DNase II Deoxyribonuclease II
- micrococcal nuclease The DNase may be recombinant human DNase or an animal sourced form (e.g. bovine) or a microbial sourced form.
- the recombinant DNase I may be dornase alpha, which is available under the tradename
- a DNase variant may be created by modifying its genetic composition, for example, by removing the singal peptide, mutating substrate binding sites or amino acid substitutionis to create hyperactive variants or more stable variants.
- DNase II or DNase-like I, II, or III their variants may be used, either in combination or alone.
- the RNase may be any enzyme tha catalyzes the hydrolytic cleavage of phosphodiester linkages in an RNA backbone.
- One such enzyme is a ribonuclease.
- ribonucleases include, but are not limited to: Ribonuclease A (RNase A); Ribonuclease H (RNase H);
- Ribonuclease I Ribonuclease I
- Ribonuclease II Ribonuclease II
- Ribonuclease III Ribonuclease III
- Ribonuclease D Ribonuclease D
- Ribonuclease L Ribonuclease L
- Ribonuclease P Ribonuclease P
- Ribonuclease PH Ribonuclease PH
- Ribonuclease PhyM Ribonuclease R
- Ribonuclease T Ribonuclease Tl
- Ribonuclease T2 Ribonuclease T2;
- Ribonuclease U2 Ribonuclease U2
- Ribonuclease VI Ribonuclease VI
- Ribonuclease V Ribonuclease V
- the RNase may be recombinant human RNase or an animal or microbial sourced form (e.g. bovine).
- An RNase variant may be created by modifying its genetic composition, for example, by removing the singal peptide, mutating substrate binding sites or amino acid substitutionis to create hyperactive variants or more stable variants.
- the nuclease may cleave only residues at the ends of nucleic acid molecules
- the nuclease may be an endonuclease, which may be used alone or in combination with another nuclease. Examples of endonucleases are lipocalin and RNase A.
- the nuclease may cleave anywhere along the chain (endodeoxyribonucleases or endoribonucleases, subsets of endonucleases).
- the nuclease may be indiscriminate about the DNA sequence at which it cuts.
- the nuclease may be sequence- specific.
- the nuclease may cleave only double-stranded nucleic acid, only single- stranded nucleic acid, or both double- stranded and single stranded nucleic acid.
- the nuclease dosage may be determined by a doctor, for example, without undue experimentation.
- the dosage can be adjusted in the event of any counter indications, tolerance, or similar conditions. Those of skill in the art can readily evaluate such factors and, based on this information, determine a particular effective concentration of the nuclease to be used as described herein.
- the nuclease may be present in the nuclease composition at between 5 ng/ml and 3 mg/ml, between 1 mg/ml and 3 mg/ml, between 2 mg/ml and 3 mg/ml, between 10 ng/ml and 900 ng/ml, between 20 ng/ml and 800 ng/ml, between 30 ng/ml and 700 ng/ml, between 40 ng/ml and 600 ng/ml, between 50 ng/ml and 600 ng/ml, between 60 ng/ml and 500 ng/ml, between 70 ng/ml and 400 ng/ml, between 80 ng/ml and 300 ng/ml, between 90 ng/ml and 200 ng/ml, between 50 ng/ml and 250 ng/ml, between 100 ng/ml and 200 ng/ml, between 150 ng/ml and 250 ng/ml, between 100 ng/ml and 150 ng/ml,
- the nuclease may be present in the nuclease composition at 10 ng/ml, 20 ng/ml, 30 ng/ml, 40 ng/ml, 50 ng/ml, 60 ng/ml, 70 ng/ml, 80 ng/ml, 90 ng/ml, 100 ng/ml, 110 ng/ml, 150 ng/ml, 200 ng/ml, 250 ng/ml, 300 ng/ml, 350 ng/ml, 400 ng/ml, 450 ng/ml, 500 ng/ml, 550 ng/ml, 600 ng/ml, 650 ng/ml, 700 ng/ml, 750 ng/ml, 800 ng/ml, 850 ng/ml, 900 ng/ml, 950 ng/ml, 1 mg/ml, 2, mg/ml, or 3 mg/ml.
- the composition may be manually delivered to
- the ophthalmic excipient may be any ophthalmic excipient.
- the ophthalmic excipient may be a buffer, tonicity adjuster, wetting agent, and/or an antioxidant.
- the buffer may be boric and/or phosphoric acid. The buffer may minimize changes to the pH of the nuclease
- the tonicity adjuster may provide an isotonic environment and may include sodium chloride, postassium chloride, magnesium chloride, and/or boric acid.
- Antioxidants include sodiummetabisulfite and EDTA, for example.
- the antioxidants may be used to help stabilize the nuclease composition.
- Wetting agents which include polyvinyl alcohol (PVA) and polysorbate 80, may allow the nuclease composition to spread over the eye.
- ophthalmic excipients include benzalkonium chloride (BAK), ethylenediaminetetraacetic acid (EDTA), purite, chlorobutanol, sodium perborate and sorbic acid, sodium perborate, purite, polyols, glycerin, polysorbate 80, dextran 70, propylene glycol, and polyethylene glycols, such as PEG- 400.
- the ophthalmic excipient may be an ointment, such as mineral oil, white petrolatum, white ointment or lanolin. Similar to the aqueous vehicles, petrolatum and mineral oil may serve as vehicles in the ointment formulations to increase ocular contact time.
- the ophthalmic excipient may provide mucin- like properties and/ or decrease the loss of the aqueous layer due to evaporation.
- the ophthalmic exipient may function as a carrier, such as a pharmaceutically acceptable carrier as described below.
- the antibiotic may be any antibiotic.
- the antibiotic may be ampicillin,
- amoxicillin/clavulanate metronidazole, clindamycin, erythromycin, gentamicin, vancomycin, ciproflaxin, clindamycin, tetracycline, an anxiolytic, amikacin, kanamycin, neomycin, netilmicin, streptomycin, tobramycin, teicoplanin, vancomycin, azithromycin, clarithromycin,
- the antibiotic may be an ophthalmically-acceptable antibiotic.
- the antiviral compound may be any antiviral.
- the antiviral compound may be abacavir, acyclovir, adefovir, amantadine, amprenavir, ampligen, arbidol, atazanavir, atripla, boceprevir, cidofovir, darunavir, delavirdine, didanosine, docosanol, edoxudine, efavirenz, emtricitabine, enfuvirtide, entecavir, famcyclovir, fomivirsen, fosamprenavir, gancyclovir, ibacitabine, imunovir, idoxuridine, imiquimod, indinavir, lamivudine, lopinavir, loviride, maraviroc, moroxydine, pencyclovir, peremivir, pleconaril, ribavirin, ritonavir, saquin
- the anti-inflammatory may be a non-steroidal or steroidal anti-inflammatory.
- the antiinflammatory may be cyclosporine or cyclosporine A.
- the cyclosporine A may be a 0.05% concentration of cyclosporine A (for example, RESTASIS ® ).
- the anti-inflammatory may be an ophthalmically-acceptable anti-inflammatory.
- Toll-like receptor 9 recognizes specific unmethylated CpG oligonucleotide (ODN) sequences that distinguish microbial DNA from mammalian DNA.
- ODN CpG oligonucleotide
- the toll-like receptor antagonist may be any oligonucleotide that can neutralize the stimulatory effect of CpG ODNs. These oligonucleotides may be characterized by three consecutive Gs downstream of a C or A. Further, the addition of a fourth G (G-tetrads) may increase the inhibitory capability of the ODN.
- the most potent inhibitory sequences are seqeuences that contain TTAGGG, for example (TTAGGG) 4 (SEQ ID NO: l). See Figure 1, for example.
- the antagonist oligonucleotide may act by disrupting the colocalization of CpG ODNs with TLR9, such as in endosomal vesicles.
- the toll-like receptor-9 antagonist may be an ophthalmically-acceptable toll-like receptor-9 antagonist.
- Type 1 interferon is part of a defensive response to viral infections and some intracellular parasites. While these proteins have therapeutic use against some viral diseases, tumors and multiple sclerosis. Type 1 interferons can be inappropriately produced in certain disease states.
- the type-1 interferon antagonist may be any compound that antagonizes or competitively inhibits type I interferon.
- the compound may be an anti-interferon a antibody, for example.
- the compound may antagonize or inhibit type 1 interferon binding to its receptor.
- the compound may antagonize or inhibit type 1 interferon binding to its receptor subunits, IFNAE-1 or IFNR-2.
- the antagonist or competitive inhibitor can block the biological activity of native interferon.
- the type-1 interferon antagonist may be an ophthalmically-acceptable type-1 interferon antagonist. (7) Cathelicidin Inhibitor
- the cathelicidin inhibitor may be any inhibitor capable of blocking or decreasing the biological activity of cathelicidin, which can stabilize extracellular DNA on the ocular surface of eyes.
- An example of a cathelicidin inhibitor is bacterial exopolysaccharide.
- the cathelicidin inhibitor may be an ophthalmically-acceptable cathelicidin inhibitor.
- the MyD88 inhibitor may be any compound that can inhibit or decrease the biological activity or expression of MyD88.
- the MyD88 inhibitor may be a peptide or small molecule that inhibits MyD88 homodimerization, such as ST2825 (Sigma Tau, Pomezia, Italy), the synthetic oligopeptide IMG2205 (Imgenex Corporation, San Diego, CA), and/or MyD88 Inhibitory Peptide (MIP).
- the MyD88 inhibitor may inhibit MyD88 binding to signaling partners.
- the MyD88 inhibitor may be a dominant negative MyD88 protein.
- the MyD88 inhibitor may be an antisense, siRNA, or a shRNA molecule that inhibits MyD88 expression.
- the neutrophil elastase inhibitor may be any compound that can inhibit or decrease the biological activity of neutrophil elastase, which is a serine protease secreted by neutrophils during inflammation.
- the inhibitor may be synthetic, natural, reversible or irreversible.
- the neutrophil elastase inhibitor may be ONO-5046, MR-889, L- 694,458, CE-1037, GW-311616 or TEI-8362.
- the neutrophil elastase inhibitor may be ONO- 6818, AE-3763, FK-706, ICI-200,880, ZD-0892 or ZD-8321.
- the neutrophil elastase inhibitor may be an ophthalmically-acceptable neutrophil elastase inhibitor.
- the nuclease compound can be incorporated into pharmaceutical compositions suitable for administration to a subject (such as a patient, which can be a human or non-human).
- the nuclease composition comprises a pharmaceutically acceptable carrier suitable for ophthalmic delivery.
- Suitable ophthalmic carriers are known to those skilled in the art and all such conventional carriers may be employed in the present invention.
- Suitable carriers that may be used to facilitate and expedite transdermal delivery of topical compositions into ocular or adnexal tissues include, but are not limited to, alcohol (ethanol, propanol, and nonanol), fatty alcohol (lauryl alcohol), fatty acid (valeric acid, caproic acid and capric acid), fatty acid ester (isopropyl myristate and isopropyl n-hexanoate), alkyl ester (ethyl acetate and butyl acetate), polyol (propylene glycol, propanedione and hexanetriol), sulfoxide (dimethylsulfoxide and decylmethylsulfoxide), amide (urea, dimethylacetamide and pyrrolidone derivative
- topically- administered compositions comprise surface adhesion molecule modulating agents including, but not limited to, a cadherin antagonist, a selectin antagonist, and an integrin antagonist.
- the composition further contains a compound selected from the group consisting of a physiological acceptable salt, poloxamer analogs with carbopol, carbopol/hydroxypropyl methyl cellulose (HPMC), carbopol-methyl cellulose, carboxymethylcellulose (CMC), hyaluronic acid, cyclodextrin, and petroleum.
- topically-administered compositions may comprise surface adhesion molecule modulating agents including, but not limited to, a cadherin antagonist, a selectin antagonist, and an integrin antagonist.
- a particular carrier may take the form of a sterile, ophthalmic ointment, cream, gel, solution, or dispersion.
- suitable ophthalmic carriers are slow release polymers, e.g., "Ocusert" polymers, "Hydron” polymers, etc.
- Stabilizers may also be used such as, for example, chelating agents, e.g., EDTA.
- Antioxidants may also be used, e.g., sodium bisulfite, sodium thiosulfite, 8-hydroxy quinoline or ascorbic acid. Sterility typically will be maintained by conventional ophthalmic preservatives, e.g., chiorbutanol, benzalkonium chloride, cetylpyridium chloride, phenyl mercuric salts, thimerosal, etc., for aqueous formulations, and used in amounts which are nontoxic and which generally vary from about 0.001 to about 0.1% by weight of the aqueous solution. Conventional preservatives for ointments include methyl and propyl parabens.
- Typical ointment bases include white petrolatum and mineral oil or liquid petrolatum. However, preserved aqueous carriers are preferred. Solutions may be manually delivered to the eye in suitable dosage form, e.g., eye drops, or delivered by suitable microdrop or spray apparatus typically affording a metered dose of medicament. Examples of suitable ophthalmic carriers include sterile, substantially isotonic, aqueous solutions containing minor amounts, i.e., less than about 5% by weight
- hydroxypropylmethylcellulose polyvinyl alcohol, carboxymethylcellulose, hydroxyethylcellulose, glycerine and EDTA.
- the solutions are preferably maintained at substantially neutral pH and isotonic with appropriate amounts of conventional buffers, e.g., phosphate, borate, acetate, tris.
- Pharmaceutically acceptable ophthalmic carriers may further comprise amounts of auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the nuclease, antibiotic compounds, anti- viral compounds, toll-like receptor antagonists, type-1 interferon antagonists, cathelicidin inhibitors, and/or a neutrophil elastase inhibitors.
- auxiliary substances such as wetting or emulsifying agents, preservatives or buffers, which may enhance the shelf life or effectiveness of the nuclease, antibiotic compounds, anti- viral compounds, toll-like receptor antagonists, type-1 interferon antagonists, cathelicidin inhibitors, and/or a neutrophil elastase inhibitors.
- compositions useful for treating or ameliorating a nucleic acid-related eye disease or one or more symptoms thereof e.g., encapsulation in liposomes, microparticles, microcapsules.
- the composition may be administered via injection.
- the composition may be injected into the eye.
- the nuclease composition may be in the form of liquid eye drops, a gel, or ointment, which may be applied directly to the ocular surface of the affected eye(s).
- the drops, gel, or ointment may be applied in accordance with instructions from a doctor and/or in accordance with dosage recommendations.
- one drop of a composition containing between 100 ng/ml and 200 ng/ml of nuclease may be administered between 1 and 10 times daily between 1 and 7 times daily, between 1 and 4 times daily, or between 1 and 3 times daily.
- the herein described nuclease composition may be delivered to the eye via contact lens.
- the composition is incorporated into or coated onto said lens.
- the composition is chemically bound or physically entrapped by the contact lens polymer.
- a color additive is chemically bound or physically entrapped by the polymer composition that is released at the same rate as the therapeutic drug composition, such that changes in the intensity of the color additive indicate changes in the amount or dose of therapeutic drug composition remaining bound or entrapped within the polymer.
- an ultraviolet (UV) absorber is chemically bound or physically entrapped within the contact lens polymer.
- the contact lens is either hydrophobic or hydrophilic.
- Exemplary materials used to fabricate a hydrophobic lens with means to deliver the compositions of the invention include, but are not limited to, amefocon A, amsilfocon A, aquilafocon A, arfocon A, cabufocon A, cabufocon B, carbosilfocon A, crilfocon A, crilfocon B, dimefocon A, enflufocon A, enflofocon B, erifocon A, fluorofocon A, flusilfocon A, flusilfocon A, flusilfocon
- Exemplary materials used to fabricate a hydrophilic lens with means to deliver the compositions of the invention include, but are not limited to, abafilcon A, acofilcon A, acofilcon
- acquafilcon A alofilcon A, alphafilcon A, amfilcon A, astifilcon A, atlafilcon A, balafilcon A, bisfilcon A, bufilcon A, comfilcon A, crofilcon A, cyclofilcon A,balilcon A, deltafilcon A, deltafilcon B, dimefilcon A, droxfilcon A, elastofilcon A, epsilfilcon A, esterifilcon A, etafilcon A, focofilcon A, galyfilcon A, genfilcon A, govafilcon A, hefilcon A, hefilcon B, hefilcon C, hilafilcon A, hilafilcon B, hioxifilcon A, hioxifilcon B, hioxifilcon C, hydrofilcon A, lenefilcon A, licryfilcon A, licryfilcon B, lidofilcon A, lidofilcon B, lotrafilcon A, lotrafilcon A
- ocufilcon D ocufilcon E
- ilcon A omafilcon A, oxyfilcon A, pentafilcon A, perfilcon A, pevafilcon A, phemfilcon A, polymacon, senofilcon A, silafilcon A, siloxyfilcon A, surfilcon A, tefilcon A, tetrafilcon A, trilfilcon A, vifilcon A, vifilcon B, and xylofilcon A.
- the composition may be administered as a solid, a paste, an ointment, a gel, a liquid, an aerosol, a mist, a polymer, a film, an emulsion, or a suspension.
- the composition may be incorporated into or coated onto a contact lens or drug delivery device, from which one or more molecules diffuse away from the lens or device or are released in a temporally- controlled manner.
- the contact lens composition may either remain on the ocular surface, e.g. if the lens is required for vision correction, or the contact lens dissolves as a function of time simultaneously releasing the composition into closely juxtaposed tissues.
- the drug delivery device is optionally biodegradable or permanent in various embodiments.
- one or more of the nuclease compositions can be packaged in a hermetically sealed container such as an ampoule or sachette indicating the quantity of the nuclease, for example.
- a hermetically sealed container such as an ampoule or sachette indicating the quantity of the nuclease, for example.
- one or more of the nuclease compositions is/are supplied as a dry sterilized lyophilized powder or water-free concentrate in a hermetically sealed container and can be reconstituted (e.g., with water or saline) to the appropriate concentration for administration to a subject.
- one or more of the compositions is supplied as a dry, sterile, lyophilized powder in a hermetically sealed container at a unit dosage of at least 0.01 mg, 0.05 mg, 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 1.5 mg, 2.0 mg, 5 mg, for example at least 10 mg, at least 15 mg, at least 25 mg, at least 35 mg, at least 45 mg, at least 50 mg, at least 75 mg, or at least 100 mg.
- the lyophilized compositions should be stored at between 2°C and 8°C in the original container and the compositions should be administered within 1 week, for example within 5 days, within 72 hours, within 48 hours, within 24 hours, within 12 hours, within 6 hours, within 5 hours, within 3 hours, or within 1 hour after being reconstituted.
- the liquid form of the administered nuclease composition is supplied in a hermetically sealed container at least 0.25 mg/ml, for example at least 0.5 mg/ml, at least 1 mg/ml, at least 2.5 mg/ml, at least 5 mg/ml, at least 8 mg/ml, at least 10 mg/ml, at least 15 mg/kg, at least 25 mg/ml, at least 50 mg/ml, at least 75 mg/ml or at least 100 mg/ml.
- the liquid form should be stored at between 2°C and 8°C in its original container.
- the pharmaceutical compositions may include a "therapeutically effective amount” or a “prophylactically effective amount” of a nuclease.
- a “therapeutically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic result.
- a therapeutically effective amount of the composition may be determined by a person skilled in the art and may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the composition to elicit a desired response in the individual.
- a therapeutically effective amount is also one in which any toxic or detrimental effects of the nuclease are outweighed by the therapeutically beneficial effects.
- prophylactically effective amount refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount will be less than the therapeutically effective amount. c. Subject
- the subject may be a mammal, which may be a human or a non-human.
- the subject may be in need of treatment for a nucleic acid-related eye disease.
- nuclease composition may be contacted with the the eye(s) of the subject suffering from a nucleic acid-related eye disease, such as DED.
- a nucleic acid-related eye disease such as DED.
- the nuclease composition may be contacted with the eye(s) by any means.
- the mode of contact with the eye may be such that the nuclease composition is applied topically or injected into the eye.
- the compositions can be formulated in a variety of forms well-known to one of skill in the art. See, e.g., Remington's Pharmaceutical Sciences and Introduction to Pharmaceutical Dosage Forms, 19th ed., Mack Pub. Co., Easton, Pa. (1995).
- the nuclease composition may be formulated pharmaceutically acceptable carrier as described herein. See Section 3(b), for example.
- the nucleic acid-related eye disease may be caused by autoimmune conditions, decreased tear production, microbial infection, a change in tear composition, and/or environmental conditions. Such conditions may decrease the rate of blinking and/or result in inadequate lubrication of the eye, for example.
- the subject may be identified as suffering from a nucleic acid-related eye disease or a related disorder by detecting a sign or symptom selected from the group consisting of dry, scratchy, stingy, itchy, burning or pressured sensations, irritation, pain, redness, inflammation, discharge, and excessive eye watering.
- the subject's tear composition may be insufficient for proper eye tissue lubrication.
- the nucleic acid-related eye disease may provide an environment on, in, or around the eye for inflammation, bacterial proliferation and/or bacterial infection.
- the nucleic acid-related eye disease may be caused by tear film, such as biofilm or mucoid film, on or in the eye. Tear film may form on materials that come in contact with the eye, such as contact lenses, or materials implanted in the eye, such as scleral buckles, intraocular lenses, keratoprostheses and glaucoma drain implants.
- the nucleic acid-related eye disease may be the result of the dysregulation of nucleic acid production and clearance mechanisms, whereby tear fluid and film nuclease level and/or activity are deficient, which allows extracellular DNA, for example, and neutrophil extracellular traps (NETS) to accumulate in tear film and drive ocular surface inflammation.
- the nucleic acid- related disease may be caused by a decrease in nuclease activity, or a decrease in the level of nuclease, in the tears as compared to normal subjects.
- the nucleic acid-related eye disease may be dry eye disease, ocular cicatricial pemphigoid (OCP), keratoconjunctivitis sicca (KCS), Sjogren syndrome (SS), Sjogren syndrome associated keratoconjunctivitis sicca, non-Sjogren syndrome associated keratoconjunctivitis sicca, keratitis sicca, sicca syndrome, xerophthalmia, tear film disorder, decreased tear production, aqueous tear deficiency (ATD), meibomian gland dysfunction (MGD), and evaporative loss, diffuse lamellar keratitis, contact lens-associated keratitis, endophthalmitis, or infectious crystalline keratopathy.
- the nucleic acid-related eye disease may be an allergic eye condition.
- the allergic eye condition may result from the presence of NETS or eosinophil extracellular traps.
- the level of nuclease in the tears or tear film of a subject having a nucleic acid-related disease may be less than 3.14 ng/ml of nuclease.
- the level of nuclease in the tears of a subject having a nucleic acid-related disease may be less than 3.00 ng/ml of nuclease; less than 2.50 ng/ml of nuclease; less than 2.00 ng/ml of nuclease; less than 1.50 ng/ml of nuclease; less than 1.00 ng/ml of nuclease; less than 3.00 ng/ml of nuclease; less than 0.50 ng/ml of nuclease; or less than 0.25 ng/ml of nuclease.
- the level of nuclease activity in the tears or tear film of a subject having a nucleic acid-related disease may be equal to, or less than, 0.05 Kunitz units.
- the level of nuclease activity in the tears of a subject having a nucleic acid-related disease may be less than 0.04 Kunitz units; less than 0.03 Kunitz units; less than 0.02 Kunitz units; less than 0.01 Kunitz units; or less than 0.05 Kunitz units.
- One Kunitz unit may be defined as the amount of nuclease enzyme that causes an increase in absorbance at 260 nm of 0.001 per mL when acting upon highly polymerized DNA at 25 °C and pH 5.0 under specified conditions.
- the tear film which may contain an accumulation of nucleic acid and NETs, may be a biofilm or a mucoid film.
- the biofilm may be produced by bacteria.
- the mucoid film may be produced by the conjunctiva of the eye.
- the mucoid film or biofilm may be present in allergic eye conditions.
- the biofilm and mucoid film on the ocular surface, or inside the eye, of a subject having a nucleic-acid-related eye disease may contain extracellular DNA, NETS, and/or neutrophils.
- the NETS may contain extracellular DNA, histones, cathelicidin, and/or neutrophil elastase.
- the DED may be any disease or disorder of the eye that can be attributed to any one of a number of factors.
- the DED to be treated is DED caused by any condition other than an alloimmune response. Alloimmune responses may result, for example, in some corneal transplant patients. More specifically, in some variations, the DED to be treated is an autoimmune DED or a DED associated with Sjogren's syndrome. The DED may be due to the presence of extracellular DNA on the ocular surface, excessively fast tear evaporation
- the dry eye disease is attributable to one or more causes selected from: aging, contact lens usage and medication usage.
- the dry eye disease is a complication of LASIK refractive surgery.
- the DED arises in a subject who has not had eye surgery of any kind, e.g., treatment of subjects in whom the DED is not caused by LASIK surgery, corneal transplant surgery, or other ocular surgeries.
- Extracellular DNA, NETs, and neutrophils may be present on the ocular surface of a DED subject and abundant in mucoid film and/or biofilm.
- the NETs may consist of extracellular DNA, histones, cathelicidin, and neutrophil elastase. Tear fluid nuclease activity may be significantly decreased in the DED subject, whereas the amount of extracellular DNA on the ocular surface may be increased. Expression of genes downstream of extracellular DNA signaling, such as TLR9, MyD88, and type I interferon, as well as the inflammatory cytokines interleukin-6 and tumor necrosis factor a may also be increased in DED patients.
- the nuclease activity deficiency may allow for extracellular DNA and NETs to accumulate in tear film, such as precorneal tear film, mucoid tear film, or biofilm, and may result in ocular surface
- Extracellular nucleic acid is a component of tear film.
- the nuclease composition described herein may be used to treat bacterial infections and inflammation related to biofilm formation, either on the ocular surface or inside the eye (intraocular).
- the nuclease composition may be contacted with the eye(s) of the subject suffering from the infection.
- the infection may be a bacterial infection or a viral infection.
- the composition may be brought into contact with the eye as described above (see Section 3(a)), such as by topical application to the ocular surface or by injection into eye. Accordingly, the composition may be used intraocularly.
- kits which may be used for treating or diagnosing a nucleic acid- related eye disease.
- the kit may comprise a nuclease.
- the nuclease may be a nuclease composition comprising an ophthalmic excipient.
- the composition may contain one or more of an antibiotic compound(s), antiviral compound(s), a toll-like receptor antagonist(s), a type-1 interferon antagonist(s), a cathelicidin inhibitor(s), and/or a neutrophil elastase inhibitor(s) in a container, for use in treatment of the affected eye(s).
- the kit may comprise a nuclease composition and one or more of an antibiotic compound(s), a toll-like receptor antagonist(s), a type-1 interferon antagonist(s), a cathelicidin inhibitor(s), and/or a neutrophil elastase inhibitor(s) in two or more containers, for use in treatment of the affected eye(s).
- the kit may comprise a pipette or filter paper as sample collection means. The pipette or filter paper may be used to collect tears from the eye surface.
- the two or more containers may be packaged together, for example, in a cardboard box.
- the kit may also include a set of usage instructions, which refer to the nuclease composition and, if present, the antibiotic compound(s), the antiviral compound(s), a toll-like receptor antagonist(s), a type-1 interferon antagonist(s), a cathelicidin inhibitor(s), and/or a neutrophil elastase inhibitor(s).
- the instructions may describe how to perform and/or monitor the method described herein.
- the method may comprise collecting a tear sample from a subject.
- the sample may be obtained by using the kit described above.
- This sample may be contacted with a dye that binds to nucleic acid, such as picogreen.
- the sample may be contacted with a nucleic acid and then contacted with the dye.
- the intensity of the color may be measured and compared to the intensity of dye fluorescence in a normal control sample.
- An increased level of dye fluorescence intensity in the sample as compared to the control may be indicative of a dry eye disease.
- the dye intensity may be indicative of the level of extracellular nucleic acid on surface of the eye.
- the dye intensity and, therefore, the level of extracellular nucleic acid may be indicative of the severity of the disease. For example, if picogreen is used, a high green color intensity, especially compared to a control (i.e. a negative control), may indicate that the subject has severe dry eye disease. Depending on the type of dye used, the level of nuclease on the eye surface may also be determined using this method.
- the present invention has multiple aspects, illustrated by the following non-limiting examples.
- Schirmer's test is a routine test conducted during ocular examination. Schimer Test consists of a thin strip of filter paper placed under lower lateral eyelid for 5 minutes. The strip of paper is then taken out and measured for amount of wetting of the paper. It is measured in millimeters. If the value is less than 5, it is diagnostic for dry eye disease. Usually after the test this strip of paper is discarded. However, in the present study, this paper was used instead of discarding it.
- the cells were fixed in 10% formaldehyde for at least half an hour.
- the slide was dipped in hematoxylin for 7 mins followed by wash. Then the slide was dipped 4 times in acid rinse followed by wash and then dipped in bluing agent for 2 mins.
- the slide is briefly washed followed by eosin dip for 2 mins. After washing the slide is air dried at room temperature, covered by coverslip and visualized under light microscope.
- Double immunostaining was performed using antibodies for (a) neutrophil elastase (Dakocytomation - Monoclonal Mouse anti-human neutrophil elastase) and histones (Santa Cruz Biotechnology, Santa Cruz, CA) along with 4',6-diamidino-2-phenylindol i.e. DAPI (Vector Labs, Burlingame, CA), (b) Myloperoxidase and histones (Santa Cruz Biotechnology, Santa Cruz, CA) along with DAPI to show the presence of NETs on the ocular surface.
- the cells on the silaine coated slides were fixed in 10 % formaldehyde at least for half an hour.
- DNase treatment Four samples from conjunctiva were collected for each patient and treated with: Sample 1 - Stained with DAPI (control); Sample 2 - Treated with DNase (100 IU/ml for 20 minutes) and stained with DAPI; Sample 3 - Treated with heat inactivated DNase (100 IU/ml for 20 minutes) and stained with DAPI; Sample 4 - Soaked in PBS and stained with DAPI.
- Study Population Symptomatic tear-deficient DED patients and asymptomatic healthy individuals with normal tear production were enrolled and provided written informed consent according to the Helsinki statement under an Institutional Review Board approved protocol. Patients were included if they complained of any DED symptom (dryness, irritation, grittiness, light sensitivity, or foreign body sensation) and additionally had severe aqueous tear deficiency, defined as Schirmer I value ⁇ 5 mm in 5 minutes (without anesthesia). Individuals were included in the control group if they had no ocular symptoms and a Schirmer I value > 12 mm in 5 minutes (without anesthesia).
- Mucoid films were collected using disposable microcapiUary glass tubes (5 ⁇ volume; Sigma- Aldrich) over the bulbar conjunctiva or from inferior conjunctival fornix. The mucoid films were spread on silane-coated slides and processed.
- Immunofluorescence staining and confocal microscopy were performed to localize molecular components of NETs and extracellular DNA (eDNA) as previously described. Slides were permeabilized for 5 minutes in 0.025% Triton X- 100 and blocked for 2 hours at room temperature with 1% bovine serum albumin (BSA) and 10% normal donkey serum in PBS. Slides were incubated overnight at 4°C with the primary antibody diluted in blocking solution (1:200). The slides were washed four times in PBS (15 min each) and incubated for 1 hour with the secondary antibody diluted in blocking solution (1:200).
- BSA bovine serum albumin
- Vectashield mounting medium with 4',6-diamidino-2- phenylindole (DAPI; Cat. #H- 1200, Vector Labs) was placed over the slides and covered with a glass coverslip.
- the primary antibodies used were: (1) mouse monoclonal anti-human neutrophil elastase (clone NP57, DAKO, Glostrup, Denmark); (2) goat polyclonal anti-histone H2B (Cat. #SC- 8650, Santa Cruz Biotechnology, Santa Cruz, CA); and (3) rabbit polyclonal anti- cathelicidin (Cat. #ab64892, Abeam, Cambridge, MA).
- the secondary antibodies used were Dylight 594-conjugated anti- mouse IgG for neutrophil elastase, (1: 1000, Jackson Immunoresearch Laboratories, West Grove, PA) and FITC 480 anti-goat IgG for histone and cathelicidin (1:200, Jackson Immunoresearch Laboratories). Specimens were analyzed using a LSM 710 META confocal microscope (Carl Zeiss Meditec GmbH, Hamburg,
- the primary antibody used was rabbit polyclonal anti-DNase 1 (1:50, Cat. #HPA010703, Sigma Prestige, St. Louis, MO).
- the secondary antibody was Dylight 594-conjugated anti- rabbit IgG. Negative controls were: (1) primary antibody omitted, (2) rabbit polyclonal IgG isotype control (Cat. #ab27427, Abeam), and (3) peptide pre-incubation with primary antibody (Peptide for Cat #HPA010703, Atlas Antibodies AB, Sweden). Imaging and analyses were performed as described above.
- PCR was performed using the GoTaq PCR kit (Cat.#M7122, Promega, Madison, WI) per the manufacturer's protocol.
- the human GAPDH gene (Cat. #PPH00150F, SA Biosciences, Frederick, MD) was amplified using gene specific primers. PCR products were electrophoresed and visualized on a 2% ethidium bromide-stained agarose gel.
- Quantification of ocular surface eDNA We used two strategies to calculate the amount of eDNA on the ocular surface. First, the total length of eDNA strands was determined in exfoliated material derived from the Schirmer test strip impressions on glass slides. Second, eDNA was extracted from the Schirmer test strip using DNase I and determined the fluorescence intensity using picogreen DNA fluorescent dye.
- eDNA was pre-amplified using RT Nano Pre AMP Kit according to the manufacturer's instructions.
- Real-time quantitative PCR qPCR was performed with SYBR using a 7900HT ABI real-time instrument. eDNA signaling gene expression and inflammatory cytokines were analyzed by real-time qPCR.
- TLR 9 toll-like receptor 9
- IFA interferon-a
- MyD88 Cat. #PPH00911A
- interferon- ⁇ IFB; Cat. #PPH00384E
- IL-6 Cat. #PPH00560B
- TNF-a Cat. #PPH00341E
- GPDH glyceraldehyde-3- phosphate dehydrogenase
- Samples were assayed in duplicate in a total volume of 25 ⁇ using the following cycling conditions: 10 minutes at 95°C, 40 cycles of 95°C for 15 seconds, and 60°C for 60 seconds.
- a human genomic DNA contamination control was used to confirm that amplification reagents were not
- CT cycle threshold
- DNase detection kit MO-BIO Laboratories, Carlsbad, CA
- FRET fluorescence resonance energy transfer
- the sequence of the oligonucleotide substrate is 5' CCC CGG ATC CAC CCC 3' (SEQ ID NO:2).
- the Cy3 and BHQ2 are close enough to quench fluorescence.
- Cy3 fluorescence is proportional to the amount of cleavage and can be used to quantify nuclease activity.
- FRET substrate 2.5 nmol in 50 ⁇ buffer solution
- the fluorescence emitted (RFU) and the rate of fluorescence change were measured using the microplate reader (Synergy HI, BioTek) at 37°C, excitation 552 nm, and emission 580 nm. Plates were agitated for 5 seconds before the readings and readings were taken at 3- second intervals for 30 minutes. For analyses, the kinetic RFU measurements for each patient were averaged over 30 minutes.
- DNase I quantification in tear fluid We used a commercially available human DNase 1 ELISA Kit (Cat. #E0100214, Life Sciences Advanced Tech, St. Russia, FL) to determine the amount of DNase I in tear fluid.
- NETs Neutrophil Extracellular Traps
- eDNA and Neutrophil extracellular traps are present on the ocular surface: H&E and immunofluorescence staining was performed on conjunctival cells from patients with severe DED. Cells were derived from test strip impressions on a glass slide after performing Schirmer I test (Fig.11, Al, A2). H&E staining showed exfoliated conjunctival cells present singly or in groups. The cells were round or oval shaped, with an eosiniophilic cytoplasm and uniform round basophilic nuclei (Fig.11, B).
- DAPI nuclear staining revealed a few sparse eDNA strands in normal subjects (Fig.11, CI) and numerous long eDNA stands in DED patients (Fig.l 1, C2). Confocal microscopy revealed neutrophils were present among the eDNA strands (Fig.l 1, D). Histone (Fig.11, El) and neutrophil elastase (Fig.11, E2) colocalized with DAPI stained eDNA strands, confirming that these were NETs (Fig.11, E4). To rule out the possibility that eDNA could be an artifact of impression cytology, analyses were performed on exfoliated buccal mucosa cells obtained using identical methodology. eDNA strands were not observed (data not shown).
- H&E and immunofluorescence staining were performed on mucoid films present on the bulbar conjunctiva/cornea (Fig.12, Al) or in the inferior fornix (Fig.12, A2). Mucoid films appeared as a frothy white mucoid collection that sometimes dispersed with blinking. A microcapillary tube was used to lift these mucoid films for analyses. In some instances, turbid white fluid was drawn in the microcapillary tube. However, the analyses still revealed similar findings. H&E showed numerous neutrophils and exfoliated cells within the mucoid films (Fig.12, Bl).
- DAPI staining showed eDNA (Fig.12, B2) and numerous neutrophil elastase positive neutrophils (Fig.12, B3).
- Neutrophil elastase (Fig.12, CI) and histone (Fig.12, C2) colocalized with DAPI-stained eDNA strands, confirming that these were NETs (Fig.12, C4).
- DAPI-stained strands contained DNA
- DAPI-stained strands from membrane slides were captured using a laser capture microdissection microscope (Fig.12, Dl and D2).
- the extracellular DAPI-stained strands contain DNA as shown by GAPDH gene product PCR amplification (Fig, 12, D3).
- cathelicidin was present within mucoid films (Fig.13, Al) and colocalized with neutrophil elastase and DAPI- stained nuclear material (Fig, 13, A4). Cathelicidin was also present within neutrophils (Fig.13, B4). Cathelicidin, nuclear material, and neutrophil elastase extrude from the neutrophil to form NETs (Fig.l3, Cl-4).
- qPCR on exfoliated conjunctival cells was performed to determine the fold change in the expression of genes downstream of eDNA signaling (Fig.14, D).
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161569604P | 2011-12-12 | 2011-12-12 | |
US201261600377P | 2012-02-17 | 2012-02-17 | |
PCT/US2012/051562 WO2013089835A1 (en) | 2011-12-12 | 2012-08-20 | Composition and method for treating nucleic acid-related eye disease |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2790722A1 true EP2790722A1 (en) | 2014-10-22 |
EP2790722A4 EP2790722A4 (en) | 2015-09-09 |
EP2790722B1 EP2790722B1 (en) | 2018-12-05 |
Family
ID=48613071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12858050.3A Active EP2790722B1 (en) | 2011-12-12 | 2012-08-20 | Composition and method for treating nucleic acid-related eye disease |
Country Status (15)
Country | Link |
---|---|
US (3) | US9867871B2 (en) |
EP (1) | EP2790722B1 (en) |
JP (1) | JP6202400B2 (en) |
KR (1) | KR101898438B1 (en) |
CN (1) | CN104220087A (en) |
AU (1) | AU2012352983B2 (en) |
BR (1) | BR112014014378A2 (en) |
CA (1) | CA2858983C (en) |
DK (1) | DK2790722T3 (en) |
ES (1) | ES2713519T3 (en) |
IL (1) | IL232999B (en) |
MX (1) | MX364495B (en) |
RU (1) | RU2642609C2 (en) |
WO (1) | WO2013089835A1 (en) |
ZA (1) | ZA201404320B (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130297023A1 (en) * | 2012-05-07 | 2013-11-07 | Hee-Jeong Im Sampen | Methods and Devices For Treating Intervertebral Disc Disease |
US9919034B2 (en) | 2014-03-28 | 2018-03-20 | Tamir Biotechnology, Inc. | Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V |
US10835598B2 (en) | 2014-08-18 | 2020-11-17 | Orgenesis Inc. | Prophylactic protection against viral infections, particularly HIV |
MX2017016368A (en) * | 2015-06-15 | 2018-04-24 | Tamir Biotechnology Inc | Pharmaceuticals for treatment of viral infections of the eye. |
EP3351263A1 (en) | 2017-01-20 | 2018-07-25 | Universitätsklinikum Hamburg-Eppendorf | Pharmaceutical preparation for treating or preventing tissue adhesion |
EP3644966A4 (en) * | 2017-06-29 | 2021-03-24 | Advaite LLC | Treatment and diagnosis of ocular surface disorders |
SG11202001445XA (en) | 2017-08-18 | 2020-03-30 | Neutrolis Inc | Engineered dnase enzymes and use in therapy |
WO2019065936A1 (en) * | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | Method for measuring amount of muc5ac in tear |
US11253395B2 (en) * | 2018-06-01 | 2022-02-22 | Aurora Tears Technology, Inc. | Systems and methods for generating and applying biomimicry tear films |
WO2019231853A1 (en) | 2018-06-01 | 2019-12-05 | Aurora Tears Technology, Inc. | Systems and methods for generating and applying biomimicry tear films |
MX2021004022A (en) | 2018-10-08 | 2021-09-10 | Neutrolis Inc | Engineering of dnase enzymes for manufacturing and therapy. |
US11058724B2 (en) | 2018-10-08 | 2021-07-13 | Neutrolis, Inc. | Methods of using DNASE1-like 3 in therapy |
US10988746B2 (en) | 2018-10-08 | 2021-04-27 | Neutrolis, Inc. | Manufacturing and engineering of DNASE enzymes for therapy |
US11352613B2 (en) | 2019-02-04 | 2022-06-07 | Neutrolis, Inc. | Engineered human extracellular DNASE enzymes |
RU2740363C1 (en) * | 2020-08-03 | 2021-01-13 | Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) | Method for assessing the effectiveness of treatment of dry eye syndrome in patients with diabetes mellitus |
BE1028712B1 (en) | 2020-10-16 | 2022-05-18 | Onelife S A | PARA-PHARMACEUTICAL OR PHARMACEUTICAL COMPOSITION ADMINISTRABLE TO A LIVING BEING, PREFERABLY A HUMAN BEING COMPRISING AT LEAST ONE ENZYME FOR THE TREATMENT AND/OR PREVENTION OF BACTERIAL INFECTIONS INVOLVING THE FORMATION OF BIOFILM |
CN115595315A (en) * | 2021-06-28 | 2023-01-13 | 四川大学华西医院(Cn) | Novel application of ribonuclease I in pain inhibition medicine |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU1575359A1 (en) | 1988-06-14 | 1991-05-15 | Институт Морфологии Человека Амн Ссср | Method of producing ribonucleotides |
DE69838452T2 (en) | 1997-07-29 | 2008-06-12 | The Solution Line, Inc., Lebanon | PEN OF RENEWED RUBBER |
GB9716376D0 (en) * | 1997-08-01 | 1997-10-08 | Isis Innovation | Artificial tear formulation |
US6759040B1 (en) * | 1997-09-12 | 2004-07-06 | University Of Maryland, College Park | Preparation and use of biofilm-degrading, multiple-specificity, hydrolytic enzyme mixtures |
US20080096817A1 (en) * | 1998-07-30 | 2008-04-24 | Regenerx Biopharmaceuticals, Inc. | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES |
MXPA03004883A (en) * | 2000-12-01 | 2004-05-04 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations. |
MXPA03008359A (en) * | 2001-03-15 | 2004-10-15 | Regenerx Biopharmaceuticals | METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN szlig;4 (Tszlig;4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES. |
US20050255144A1 (en) * | 2003-04-09 | 2005-11-17 | Directcontact Llc | Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases |
US20050089546A1 (en) | 2003-09-16 | 2005-04-28 | Dick Wurtman | Compositions and methods comprising complex carbohydrate and alpha-lactalbumin |
EP1753445A4 (en) * | 2004-05-06 | 2009-05-20 | Molichem Medicines Inc | Treatment of ocular diseases and disorders using lantibiotic compositions |
WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
US20080139545A1 (en) * | 2006-05-22 | 2008-06-12 | Won-Taek Choe | Formulation to treat ear infection |
EP2114460B1 (en) * | 2007-02-15 | 2014-07-16 | National Jewish Health | Compositions for the disruption of biofilms |
WO2009002790A2 (en) * | 2007-06-26 | 2008-12-31 | Bausch & Lomb Incorporated | Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye |
ES2493641T3 (en) | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Nasal administration of aqueous corticosteroid solutions |
TW200927192A (en) | 2007-11-19 | 2009-07-01 | Alcon Res Ltd | Use of TRPV1 receptor antagonists for treating dry eye and ocular pain |
GB2477914B (en) * | 2010-02-12 | 2012-01-04 | Univ Newcastle | Compounds and methods for biofilm disruption and prevention |
-
2012
- 2012-08-20 DK DK12858050.3T patent/DK2790722T3/en active
- 2012-08-20 WO PCT/US2012/051562 patent/WO2013089835A1/en active Application Filing
- 2012-08-20 BR BR112014014378A patent/BR112014014378A2/en not_active Application Discontinuation
- 2012-08-20 ES ES12858050T patent/ES2713519T3/en active Active
- 2012-08-20 RU RU2014128564A patent/RU2642609C2/en active
- 2012-08-20 CA CA2858983A patent/CA2858983C/en active Active
- 2012-08-20 CN CN201280069247.8A patent/CN104220087A/en active Pending
- 2012-08-20 US US14/362,589 patent/US9867871B2/en active Active
- 2012-08-20 MX MX2014007103A patent/MX364495B/en active IP Right Grant
- 2012-08-20 KR KR1020147019155A patent/KR101898438B1/en active IP Right Grant
- 2012-08-20 AU AU2012352983A patent/AU2012352983B2/en active Active
- 2012-08-20 JP JP2014547214A patent/JP6202400B2/en active Active
- 2012-08-20 EP EP12858050.3A patent/EP2790722B1/en active Active
-
2014
- 2014-06-08 IL IL232999A patent/IL232999B/en active IP Right Grant
- 2014-06-11 ZA ZA2014/04320A patent/ZA201404320B/en unknown
-
2017
- 2017-01-03 US US15/397,595 patent/US10328129B2/en active Active
-
2019
- 2019-06-17 US US16/442,739 patent/US11376312B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2858983C (en) | 2020-06-09 |
KR101898438B1 (en) | 2018-09-14 |
US11376312B2 (en) | 2022-07-05 |
US20170106057A1 (en) | 2017-04-20 |
AU2012352983B2 (en) | 2017-09-21 |
US20190314461A1 (en) | 2019-10-17 |
BR112014014378A2 (en) | 2020-05-19 |
US20150010524A1 (en) | 2015-01-08 |
KR20140101857A (en) | 2014-08-20 |
CA2858983A1 (en) | 2013-06-20 |
MX364495B (en) | 2019-04-29 |
EP2790722A4 (en) | 2015-09-09 |
IL232999B (en) | 2019-03-31 |
DK2790722T3 (en) | 2019-03-25 |
EP2790722B1 (en) | 2018-12-05 |
ZA201404320B (en) | 2015-11-25 |
JP6202400B2 (en) | 2017-09-27 |
US9867871B2 (en) | 2018-01-16 |
AU2012352983A1 (en) | 2014-07-03 |
RU2642609C2 (en) | 2018-01-25 |
JP2015506920A (en) | 2015-03-05 |
RU2014128564A (en) | 2016-02-10 |
MX2014007103A (en) | 2015-05-11 |
US10328129B2 (en) | 2019-06-25 |
IL232999A0 (en) | 2014-07-31 |
ES2713519T3 (en) | 2019-05-22 |
WO2013089835A1 (en) | 2013-06-20 |
CN104220087A (en) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11376312B2 (en) | Composition and method for treating nucleic acid-related eye disease | |
Sonawane et al. | Ocular surface extracellular DNA and nuclease activity imbalance: a new paradigm for inflammation in dry eye disease | |
Arranz-Valsero et al. | IL-6 as a corneal wound healing mediator in an in vitro scratch assay | |
Baudouin et al. | In vitro and in vivo experimental studies on trabecular meshwork degeneration induced by benzalkonium chloride (an American Ophthalmological Society thesis) | |
US10105441B2 (en) | Method for inhibiting or reducing dry eye disease by IL-1Ra | |
Al-Saedi et al. | Dry eye disease: present challenges in the management and future trends | |
Jiang et al. | Bone marrow mesenchymal stem cell-derived exosomal miR-25 regulates the ubiquitination and degradation of Runx2 by SMURF1 to promote fracture healing in mice | |
US20210322457A1 (en) | Treatment and diagnosis of ocular surface disorders | |
US20190169243A1 (en) | Silk-derived protein for treating inflammation | |
JP6544806B2 (en) | Treatment and diagnosis of eye disease | |
Walsh et al. | Identification of the molecular chaperone, heat shock protein 1 (chaperonin 10), in the reproductive tract and in capacitating spermatozoa in the male mouse | |
WO2009002790A2 (en) | Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye | |
JP5986116B2 (en) | Molecular targets for healing or treating wounds | |
CN107428805B (en) | Short synthetic peptides and their use for the treatment and/or prevention of dry eye | |
US20220288028A1 (en) | A therapeutic approach for treating non-infectious ocular immunoinflammatory disorders | |
US20230134843A1 (en) | Treatment of stem cell deficiency | |
Das et al. | Oral administration of S-nitroso-L-glutathione (GSNO) provides anti-inflammatory and cytoprotective effects during ocular bacterial infections | |
TW202228726A (en) | A use of pharmaceutical composition for preparing drug of treating ocular surface diseases | |
Groleau | Understanding and treating herpes simplex virus Type 1 corneal infections | |
Tahmaz | Treatment of ocular graft-versus-host disease with autologous serum eye drops | |
IL222470A (en) | Methods for determining fertility status in a male subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140711 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150810 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 38/43 20060101AFI20150803BHEP Ipc: A61K 9/08 20060101ALI20150803BHEP Ipc: A61P 27/02 20060101ALI20150803BHEP Ipc: A61P 27/00 20060101ALI20150803BHEP |
|
TPAC | Observations filed by third parties |
Free format text: ORIGINAL CODE: EPIDOSNTIPA |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20161220 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20180621 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 1072218 Country of ref document: AT Kind code of ref document: T Effective date: 20181215 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012054490 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: VALIPAT S.A. GEVERS SA, CH |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20190318 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: RUE DES NOYERS 11, 2000 NEUCHATEL (CH) |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190305 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190305 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2713519 Country of ref document: ES Kind code of ref document: T3 Effective date: 20190522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190306 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190405 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20190405 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012054490 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
26N | No opposition filed |
Effective date: 20190906 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20190820 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: UEP Ref document number: 1072218 Country of ref document: AT Kind code of ref document: T Effective date: 20181205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120820 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20181205 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20230826 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: TR Payment date: 20230808 Year of fee payment: 12 Ref country code: IT Payment date: 20230822 Year of fee payment: 12 Ref country code: IE Payment date: 20230828 Year of fee payment: 12 Ref country code: GB Payment date: 20230828 Year of fee payment: 12 Ref country code: FI Payment date: 20230825 Year of fee payment: 12 Ref country code: ES Payment date: 20230901 Year of fee payment: 12 Ref country code: CH Payment date: 20230903 Year of fee payment: 12 Ref country code: AT Payment date: 20230802 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20230827 Year of fee payment: 12 Ref country code: FR Payment date: 20230825 Year of fee payment: 12 Ref country code: DK Payment date: 20230829 Year of fee payment: 12 Ref country code: DE Payment date: 20230829 Year of fee payment: 12 Ref country code: BE Payment date: 20230828 Year of fee payment: 12 |